Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Fatigue Sections
Author Bio
Introduction
Currently selected section: Fatigue in Medical Illness
Fatigue Defined
Research Questions
Measurement and Assessment
Fatigue Measurement
Related Constructs
Designing Fatigue Surveys
Case Definition
Data Collection
Maximizing Completion
Designing Intervention Trials
Controlled Trials
Selecting Study Procedures
Issues in Data Analysis
Conclusion




Chapter 9: Fatigue: The Problem of Fatigue in Medical Illness
        

Efforts to address the problem of fatigue are part of a steadily increasing focus on the quality of life concerns of patients with serious illness. The management of fatigue can be broadly subsumed under the therapeutic model known as palliative care, which is primarily focused on these quality-of-life concerns. Palliative care is an interdisciplinary approach that emphasizes the comprehensive management of the physical, psychological, social and spiritual needs of patients with progressive incurable illnesses and their families (Billings, 1998). To optimize palliative care, clinicians attempt to ensure that physical comfort is a priority, that practical needs are addressed, that psychosocial and spiritual distress is managed, values and decisions are respected, and opportunities become available for growth and closure. Although the need for palliative care intensifies as death approaches, the concerns addressed by this model, including fatigue, are relevant at any point during the course of a life-threatening illness.

The prevalence rates for fatigue in populations with serious medical illnesses are far higher than the base rate of less than 20% that exists in the general population (Pawlikowska et al., 1994; Loge et al., 1998). A recent population-based survey observed that 78% of cancer patients had experienced significant fatigue (Vogelzang et al., 1997) and that the symptom had adversely affected function in most of these patients. Other surveys confirm that more than 75% of patients with metastatic neoplasms report clinically significant fatigue (Curtis et al., 1991; Dunphy and Amesbury, 1990; Dunlop, 1989; Portenoy et al., 1994; Ventafridda et al., 1990), and that prevalence rates even higher than this occur in association with chemotherapy, radiation therapy, and the administration of biologic response modifiers such as the interferons and interleukins (Greenberg et al., 1992; Haylock and Hart, 1979; Hickok et al., 1996; Smets et al., 1996; Irvine et al., 1991; Irvine et al., 1994; Dean et al., 1995; Pickard-Holley, 1991). A few studies have documented the potential for chronic fatigue in long-term cancer survivors (Fobair et al., 1986; Joly et al., 1996; Berglund et al., 1991; Okuyama et al., 2000; Loge et al., 1999; Loge et al., 2000). Most of these surveys demonstrate relationships between fatigue and various phenomena related to impaired quality of life, including negative mood, diminished performance status, and sleep disturbance.


Page 3 of 45

Previous Section